6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one | 1005403-13-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one
• 英文别名: 6-(3-chloropropoxy)-1-tetralone；6-(3-chloropropoxy)-3,4-dihydro-2H-naphthalen-1-one
• CAS: 1005403-13-3
• 化学式: C₁₃H₁₅ClO₂
• 分子量: 238.714
• InChiKey: OVVPTWVNHMVQJE-UHFFFAOYSA-N

物化性质

• 沸点：
  403.3±40.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one 在 potassium carbonate 、 溶剂黄146 、 sodium iodide 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists

  摘要：

  A novel class of benzocinnolinones analogs of irdabisant were designed and synthesized as histamine H3R antagonists/inverse agonists. Modifications to the pyridazinone portion of the core and linker led to the identification of molecules with excellent target potency and selectivity with improved rat pharmacokinetic properties and reduced potential hERG liabilities. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.001
• 作为产物：
  描述：

  6-羟基-1-四氢萘酮 、 1-溴-3-氯丙烷 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 14.0h， 以73%的产率得到6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one
  参考文献：
  名称：

  Pyridizinone derivatives

  摘要：

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。

  公开号：

  US20080027041A1

文献信息

• Pyridizinone derivatives
  申请人：Hudkins L. Robert

  公开号：US20080027041A1

  公开（公告）日：2008-01-31

  The present invention provides compounds of formula (I*): their use as H 3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。
• Heteroarylpiperidines, pyrrolidines and piperazines and their use as
  申请人：Hoechst-Roussel Pharmaceuticals, Inc.

  公开号：US05364866A1

  公开（公告）日：1994-11-15

  Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.

  吡啶基哌啶、吡咯烷和哌嗪等杂环哌啶类化合物可用作抗精神病和镇痛剂。这些化合物特别适用于通过向哺乳动物施用其中一种化合物的抗精神病有效量来治疗精神病。这些化合物也可通过向哺乳动物施用其中一种化合物的镇痛有效量来用作镇痛剂。
• Pyridazinone Derivatives
  申请人：Bacon Edward R.

  公开号：US20110288075A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括神经退行性疾病、睡眠/清醒障碍、注意力缺陷多动障碍和认知/认知障碍等。
• PYRIDAZINONE DERIVATIVES
  申请人：Bacon Edward R.

  公开号：US20140142088A1

  公开（公告）日：2014-05-22

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.

  本发明涉及新型吡啶酮衍生物，可介导酶活性。特别地，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括但不限于神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动障碍和认知方面。
• Aryl pyridazinone derivatives and their use as H3 receptor ligands
  申请人：Bacon Edward R.

  公开号：US08586588B2

  公开（公告）日：2013-11-19

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物及/或其药学上可接受的盐可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面有效，包括神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动症和认知/认知障碍等。